Rituximab, developed in partnership by Roche and Biogen Idec, was the first anti-CD20 monoclonal antibody to be approved for the treatment of non-Hodgkin lymphomas. It works by specifically ...

In the case we report, this dilemma was resolved by successful treatment with rituximab. Rituximab has established benefit for the treatment of lupus and rheumatoid arthritis, for which it is ...

病例信息患者吕*，男，33岁，主因“发现血肌酐升高3月，周身水肿半月”入院。现病史：患者入院前3月因“原发性血小板减少症”复诊时发现血肌酐升高，为106μmol/L，当时无尿量及尿色改变，无下肢水肿，无恶心、呕吐，无胸闷憋、气，无脱发、光过敏，无皮疹、关节肿痛等，患者未行诊治。入院前半月患者无明显诱因出现周身水 ...

SAVANNAH, Ga. -- One year after starting efgartigimod (Vyvgart) treatment, most generalized myasthenia gravis (gMG) patients ...

In the years since targeted treatments for CLL were introduced, their use in the second line has increased, but chemotherapy ...

The study found that the price tag for the second-generation Bruton tyrosine kinase inhibitor would need to be reduced by 30% ...

A study found that switching from rituximab to biosimilar CT-P10 is safe and effective for patients with systemic lupus ...

Most patients were able to stay with treatment once starting it, with retention rates of about 60% to 80% through 12 months (rituximab had the highest retention and IL-6 inhibitors the lowest).

A 3-year follow-up of patients with refractory/relapsed indolent non-Hodgkin (NHL) treated with a combination of magrolimab and rituximab showed no new treatment-emergent adverse events ...

A phase 1b trial showed promising results among patients with relapsed or refractory chronic lymphocytic leukemia.

JAK inhibitors were found to be either marginally more effective or as effective as biologic DMARDs in reducing pain in ...

A 64-year-old man experienced severe visual distortions, resembling a Picasso painting, and various distressing symptoms for ...